EGFR and lung adenocarcinoma: NGS was used to interrogate mutations within hotspot regions of 46 cancer-related genes in lung adenocarcinoma samples from 13 and 16 EGFR-TKI-treated patients who had short (< 3 months) and long (> 1 year) PFS, respectively.